Genetic
T-Cell Infusion
T-Cell Infusion is a genetic therapy with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
withdrawn133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
withdrawnphase_1
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
NCT02274506
completedphase_1
CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)
NCT01653717
completedphase_1
Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells
NCT01362452
Clinical Trials (3)
Showing 3 of 3 trials
NCT02274506Phase 1
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
NCT01653717Phase 1
CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)
NCT01362452Phase 1
Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells
All 3 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 3